## COLLAGEN DIAGNOSTIC LABORATORY

### **UW LABORATORY FOR PRECISION DIAGNOSTICS**

Peter H. Byers, MD, University of Washington, Lab H-561 Health Sciences, 1959 NE Pacific St, Seattle, WA 98195 Main Phone (206) 543-0459; Genetic Counselors (206) 543-5464; Fax (206) 616-1899; www.uwcpdx.org

### LABORATORY TEST REQUISITION FORM

PATIENT INFORMATION	REPORTING RESULTS							
NAME:	REFERRING PHYSICIAN (REQUIRED):							
DOB:	NAME:							
SEX: ☐ MALE ☐ FEMALE	NPI #:							
YOUR PATIENT ID#:	PHYSICIAN SPECIALTY:							
ADDRESS:	GENETIC COUNSELOR:							
	INSTITUTION:							
CITY: STATE: ZIP:	ADDRESS:							
PHONE:	CITY: STATE: ZIP:							
	COUNTRY:							
SAMPLE TYPE:	PHONE:							
<u> </u>	FAX:							
☐ Blood ( <b>PREFERRED</b> )5-7cc, purple top EDTA	EMAIL:							
DNA (minimum 5μg)								
☐ Saliva	REFERRING LAB:							
	SEND OUT COORDINATOR:							
	ADDRESS:							
CVS Cells (2 T-25 flasks, cultured)	CITY: STATE: ZIP:							
Cultured fibroblasts	COUNTRY:							
☐ Stored cells (CDL Repository)	PHONE:							
	FAX:							
testing and for educational purposes. De-identified data from tested individuals may be submitted to clinical genetic data registries and/or for publication. Individuals may refuse to allow CDL to use their information and specimen by signing below. A description of this testing policy and research approach is available at <a href="https://www.uwcdl.org">www.uwcdl.org</a> OPT OUT SIGNATURE DATE								
CLINICAL INFORMA	ATION – PLEASE ATTACH CLINIC NOTE							
SUSPECTED DIAGNOSIS:								
☐ Osteogenesis Imperfecta ☐ Ehlers-Danlos Syn	drome 🔲 Marfan Syndrome 🔲 Loeys-Dietz Syndrome							
☐ Familial Aneurysm Syndrome ☐ Other:								
CLINICAL DESCRIPTION – PLEASE ATTACH CLINIC	C NOTE:							
☐ Blue sclerae ☐ Hearing Loss ☐ High arched								
☐ Translucent skin ☐ Easy bruising ☐ Atrophic so	1							
☐ Bone deformity ☐ Short Stature ☐ Joint hyper								
	mobility joint dislocations congernal contractures							
Fractures (age and location):	Ilantina).							
☐ Vascular Event: dissection, aneurysm, rupture (age an	a iocation).							
Other findings/history:								
Positive family history (please include pedigree)								
Special Instructions and Additional Information (if pre-	natal, include EDD):							

### TEST REQUESTED (See website for current costs and CPT codes)

	vn Mutation/Variant Testing e of Relative (Proband):	(Please provide copy of 1	eport if testing done CDL#:	at another laboratory)
	onship to Proband:		Gene:	Mutation/Variant:
Panels	and single gene tests include	both sequencing and	deletion/duplic	ation analysis by next-generation sequencing
Osteo	ogenesis Imperfecta (OI) and	genetic bone disorder	rs	
	Autosomal Dominant OI Panel	(COL1A1, COL1A2, IFIT	M5)	
	OI and Genetic Bone Disorders	Panel		
	(ALPL, B3GAT3, B4GALT7, BN	IP1, COL1A1, COL1A2, C ), NBAS, P3H1, P4HB, PL	OD2, PLOD3, PLS	FAM46A/TENT5A, FGFR3, FKBP10, GORAB, 3, PPIB, RUNX2, SEC24D, SERPINF1, SERPINH1,
I	ndividual Genes:			
	COL1A1 and COL1A2			
	IFITM5			
	Caffey Disease (COL1A1 c.3040	C>T), Sanger sequencing		
	Hypophosphatasia (ALPL)			
	X-Linked Osteoporosis (PLS3)			
Oste	opetrosis Panel			
	(AMER1, CA2, CLCN7, CTSK, I	FAM20C, FERMT3, LEMI	O3, LRP5, OSTM1,	PLEKHM1, SNX10, TCIRG1, TNFRSF11A, TNFSF11)
Ehlei	rs-Danlos Syndromes (EDS)			
	<b>J</b>		1S, CHST14, COL1	1A1, COL1A2, COL3A1, COL5A1, COL5A2, DSE,
	Classical and Vascular EDS Pa	nel (COL5A1, COL5A2, C	OL3A1)	
	Classical EDS (COL5A1 and Co	OL5A2)	·	
	Vascular EDS (COL3A1)			
	Arthrochalasia EDS (Exon 6 C	OL1A1/COL1A2), Sanger	sequencing	
	Dermatosparaxis EDS (ADAM	TS2)		
	Kyphoscoliotic EDS (PLOD1 a	nd FKBP14)		
	Periodontal EDS (C1S and C1)	₹)		
Com	plex EDS-like Disorders			
	(B3GALT6, B4GALT7, B3GAT3	, CHST14, CHST3, XYLT	1)	
Vaso	cular Genetic Disorders			
	Arterial Aneurysm Panel (ACTA2, BGN, CBS, COL1A1, PRKG1, SKI, SLC2A10, SMAD.			A, MFAP5, MYH11, MYLK, NOTCH1, PLOD3, 1, TGFBR2)
	Marfan Syndrome and Loeys-	Dietz Syndrome Panel (Fl	3N1, SMAD2, SMA	AD3, SMAD4, TGFB2, TGFB3, TGFBR1, TGFBR2)
	Marfan syndrome (FBN1)			
	COL4A1 and COL4A2 Related	Disorders (COL4A1 and	COL4A2)	
Cuti	is Laxa Panel			
	(ALDH18A1, ATP6V0A2, ATP	6V1A, ATP6V1E1, ATP7A	, EFEMP2, ELN, F	BLN5, GORAB, LTBP4, PYCR1, RIN2, SLC2A10)
Ecto	ppia Lentis Panel			
	(ADAMTS10, ADAMTS17, AL	PAMTSL4, CBS, FBN1)		
Alp	ort Syndrome			
	Alport Syndrome Panel (COL	4A3, COL4A4, COL4A5)		
	X-Linked Alport Syndrome (	COL4A5)		
Stic	ckler Syndrome			
	Stickler Panel (COL2A1, COL	9A1, COL9A2, COL9A3, C	OL11A1, COL11A	2)
Oth	ner Tests			
	Maternal Cell Contamination	n Studies (fragment anal	vsis)	
	Targeted pre-mRNA Splicing			
	angerea pre mini tri opitelli	, , oro (currented tibl	uoto requireu)	

# COLLAGEN DIAGNOSTIC LABORATORY

### **BILLING INFORMATION**

### Requested laboratory testing will be initiated only AFTER accurate billing information is provided.

Canadian samples: Providers must acquire approval of all tests, including reflex testing, before submitting samples.

BILL INSTITUTION: <u>INSTITUTIONAL BILLING</u>						
Institution Name:						
Tax ID Number:	PC	D#:				
City:	State:	ZIP:				
Phone:	Fax:					
Send Result Report:						
BILL PATIENT: SELF-P.	AY or INTERN	ATIONAL S	AMPLES			
Check (payable to UW F	hysicians) or Mo	ney Order An	nount (USD):			
Credit Card: Please co	ntact CDL billir	ıg at (206) 685	-5007 to provide credit	card information over a se	ecure line.	
Electronic Funds Trans	fer (EFT) (See w	ebsite for deta	nils) EFT Amount:	USD		
BILL INSURANCE: PATIENT INSURANCE *Patient needs to sign billing consent below*  Preauthorization is required for all insurance billing over \$600.00 (note testing is not started until pre-authorization complete)  Do insurance preauthorization PROCEED if approved; include PreAuth Form. Clinic notes are required.						
Preauthorization alre	ady obtained; P	reAuth appro	val#	At	ttach copy of P.A.	
<b>Please attach a copy of c</b> Name on Policy:	ard for all insi	ırance billing	,			
•	Self Parent	•	Other (please specify	<sup>7</sup> ):		
Cardholder DOB:	Dates of Co	verage:				
Patient Policy ID#:						
Group Name:		Group #:				
Insurance Co. Name:						
*Patient Insurance Billing Consent:  I authorize the CDL to release to my designated insurance carrier, health plan, or third party administrator the information on this form and any other information provided by my health care provider necessary for reimbursement. I assign and authorize insurance payments to the CDL. I understand my insurance carrier may not approve and reimburse my medical genetic services in full due to usual and customary rate limits, benefit exclusions, coverage limits, lack of authorization, medical necessity, or otherwise. I understand I am responsible for fees not paid in full, co-payments, and policy deductibles except where my liability is limited by contract or State or Federal law. A duplicate or faxed copy of this authorization is considered the same as the original document.						
Patient Signature:			Date:			
BILL MEDICARE: Medicare does not pre-authorize under any circumstances.						
A completed Advance Beneficiary Notice (ABN) is required for Medicare patients (see website).						

### SHIP SAMPLE OVERNIGHT TO:

Peter H. Byers, MD
UW Laboratory for Precision Diagnostics
H-561, Health Science Bldg.
1959 NE Pacific Street
Seattle, WA 98195